Companies · Other Health Care

A&K Global Health LLC

NEW YORK · Other Health Care

Diligence memoA one-page analyst read on A&K Global Health LLC — recommendation, valuation, rhythm, risks.→
$10.0M
Total raised · real
1
Rounds
—
Latest step-up
Top 25%
Sector rank · raised
Series A
Latest stage · inferred · Wed Dec 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

A&K Global Health LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.74× the median modeled value of Series A Other Health Care companies in 2010–2012 (199 peers) — value vs value, same stage and era.
Dormant
  • Last raise 13.6 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

A&K Global Health LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
13.8 yr record
Peak capital year was 2012 with $10.0M across 1 filings.
Market position
ahead of 76% of Other Health Care peers
Capital scale is ahead of 76% of Other Health Care peers; modeled value is above 88% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2012: $10.0M across 1 filings.
  • Largest single filing was $10.0M on 2012-12-05.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

A&K Global Health LLC is one of 5377 Other Health Care companies tracked from NEW YORK. By capital raised it ranks in the upper tier (ahead of 76% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2012-12-05 Raised $10M (real) Modeled valuation $202M (est)$10M$202MSeries A2012

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$10.0M · 2012

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$201.8M
Base estimate est.
$12.8M
Conservative case
$1.1B
Upside case
$45.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
6.0 yr
Elapsed time used
13.6 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
13.8 yr
On record since
2012
First round
1
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▲ 4.1× above median
This company$10.0M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage)▲ 1.8× above median
This company$10.0M
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages)▲ 9.1× above median
This company$201.8M
Sector median$22.1M

Raised more than 76% of sector peers (real $). Modeled value above 88% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #32 of 199.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Barrx Medical Inc · Series A Raised $15.0M · modeled $302.7M (est)Icad Inc · Series A Raised $27.1M · modeled $302.7M (est)Cas Medical Systems Inc · Series A Raised $16.9M · modeled $302.7M (est)Cardiosolutions Inc · Series A Raised $18.5M · modeled $300.3M (est)Ophthonix Inc · Series A Raised $24.7M · modeled $283.4M (est)FMS Watertown, LLC · Series A Raised $13.7M · modeled $277.2M (est)Flowood Vascular Access, LLC · Series A Raised $13.7M · modeled $277.2M (est)Cardiovascular Systems Inc · Series A Raised $58.5M · modeled $272.4M (est)HemaSource Holdings LLC · Series A Raised $13.5M · modeled $272.2M (est)OMNI Home Health Acquisition, LLC · Series A Raised $12.6M · modeled $253.2M (est)Integrated Sleep Holdings Inc · Series A Raised $12.4M · modeled $249.9M (est)AngioScore Inc. · Series A Raised $12.0M · modeled $242.2M (est)A&K Global Health LLC (this company) Raised $10.0M · modeled $201.8M (est)A&K Global Health LLC
CompanyStageRaised · realValue · estvs peer med.
Barrx Medical IncSeries A$15.0M$302.7M2.60×
Icad IncSeries A$27.1M$302.7M2.60×
Cas Medical Systems IncSeries A$16.9M$302.7M2.60×
Cardiosolutions IncSeries A$18.5M$300.3M2.58×
Ophthonix IncSeries A$24.7M$283.4M2.44×
FMS Watertown, LLCSeries A$13.7M$277.2M2.38×
Flowood Vascular Access, LLCSeries A$13.7M$277.2M2.38×
Cardiovascular Systems IncSeries A$58.5M$272.4M2.34×
HemaSource Holdings LLCSeries A$13.5M$272.2M2.34×
OMNI Home Health Acquisition, LLCSeries A$12.6M$253.2M2.18×
Integrated Sleep Holdings IncSeries A$12.4M$249.9M2.15×
AngioScore Inc.Series A$12.0M$242.2M2.08×
A&K Global Health LLC this companySeries A$10.0M$201.8M1.74×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$10.0M2012-12-05$45.5M$201.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$10.0M2012-12-05
    • First recorded raise — entered as Series A.
Intelligence
—
Modeled next raise
$16.0M
Modeled next size est.range $10.4M–$25.6M
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
WESLEY EDENS—1 other2012-12
Geoffrey Kent——2012-12
Mark Erwin——2012-12
William Darwin——2012-12
Registry & provenance

A&K Global Health LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1564251
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Autonomy HealthCare, LLCOther Health CareSeries A$10.0M$201.8Msame sector · same stage
ConsumerMedical, Inc.Other Health CareSeries A$10.0M$201.8Msame sector · same stage
Elixicure Inc.Other Health CareSeries A$10.0M$146.3Msame sector · same stage
Eyevensys S.A.S.Other Health CareSeries A$10.0M$136.8Msame sector · same stage
HCPlexus, Inc.Other Health CareSeries A$10.0M$201.8Msame sector · same stage
Health Informatics International, LLCOther Health CareSeries A$10.0M$201.8Msame sector · same stage
Medscient LLCOther Health CareSeries A$10.0M$201.8Msame sector · same stage
Milestone Scientific Inc.Other Health CareSeries A$10.0M$201.8Msame sector · same stage
Frequently asked
How much funding has A&K Global Health LLC raised?
A&K Global Health LLC has raised approximately $10.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is A&K Global Health LLC's estimated valuation?
Provath's modeled valuation for A&K Global Health LLC is approximately $201.8M (modeled range $12.8M–$1.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is A&K Global Health LLC at?
A&K Global Health LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Dec 05.
What does A&K Global Health LLC do and where is it based?
A&K Global Health LLC operates in the Other Health Care sector, based in NEW YORK.
Explore related

See where A&K Global Health LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at A&K Global Health LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.